Skip to Content

Smith & Nephew PLC ADR SNN

Morningstar Rating
$23.84 −0.17 (0.71%)
View Full Chart
Unlock our analysis with Morningstar Investor

Company Report

Smith & Nephew Racks Up Consistent Operational Gains

Impressive innovation has allowed Smith & Nephew to carve out a slice of the orthopedic, sports medicine, and wound care markets. Though the company is substantially smaller than the dominant orthopedic competitors, it has punched above its weight in terms of introducing meaningful innovation with its hip implants and knee replacements. For example, its Oxinium technology has demonstrated lower rates of revisions in hip replacements. The firm has also commercialized Regeneten, an implant that facilitates the growth of tendon-like tissue.

Price vs Fair Value

SNN is trading at a 37% discount.
Price
$23.84
Fair Value
$96.00
Uncertainty
Medium
1-Star Price
$44.50
5-Star Price
$97.20
Economic Moat
Jrkyb
Capital Allocation
Jmmmgkhq

Bulls Say, Bears Say

Bulls

Smith & Nephew participates in the fast-growing sports medicine arena thanks to its extensive arthroscopy portfolio.

Bears

Smith & Nephew's attempted shift to the lower-cost Syncera distribution model in the U.S. was disappointing, which leaves the firm in a tenuous competitive position for large joint replacement.

Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if SNN is a good fit for your portfolio.

News

Trading Information

Previous Close Price
$24.01
Day Range
$23.8024.02
52-Week Range
$21.5333.09
Bid/Ask
$23.57 / $23.84
Market Cap
$10.42 Bil
Volume/Avg
834,483 / 918,287

Key Statistics

Price/Earnings (Normalized)
13.19
Price/Sales
1.89
Dividend Yield (Trailing)
3.12%
Dividend Yield (Forward)
3.12%
Total Yield
3.12%

Company Profile

Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 41% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 29% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Sector
Healthcare
Industry
Medical Devices
Stock Style Box
Mid Core
Total Number of Employees
18,452

Competitors

Valuation

Metric
SNN
SYK
ZBH
Price/Earnings (Normalized)
13.1930.8915.78
Price/Book Value
2.016.691.97
Price/Sales
1.896.133.38
Price/Cash Flow
11.1529.8412.65
Price/Earnings
SNN
SYK
ZBH

Financial Strength

Metric
SNN
SYK
ZBH
Quick Ratio
0.670.860.65
Current Ratio
1.771.581.61
Interest Coverage
2.8411.326.30
Quick Ratio
SNN
SYK
ZBH

Profitability

Metric
SNN
SYK
ZBH
Return on Assets (Normalized)
7.27%10.75%7.45%
Return on Equity (Normalized)
13.79%23.27%12.87%
Return on Invested Capital (Normalized)
9.92%14.37%9.78%
Return on Assets
SNN
SYK
ZBH
See how this stock stacks up to its competitors with Morningstar Investor

Medical Devices Industry Comparables

Ticker
Name
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
ABT
Abbott LaboratoriesSvgdlpdsqRvljtq$182.7 Bil
SYK
Stryker CorpCblcnymvdJhdn$124.6 Bil
MDT
Medtronic PLCQnmdcnfcjXxgxrq$105.2 Bil
BSX
Boston Scientific CorpXqslmwpRcbzwy$99.0 Bil
DXCM
DexCom IncJmzgcjnzlJbqz$51.8 Bil
EW
Edwards Lifesciences CorpQlzsdwpfqRxzmj$51.7 Bil
ZBH
Zimmer Biomet Holdings IncChfqskdnCvdgk$24.5 Bil
ALGN
Align Technology IncWwntjyzqsDslxls$22.5 Bil
PHG
Koninklijke Philips NV ADRPdbkslyqcLxnrtpj$18.3 Bil
PODD
Insulet CorpDgfcttjnpQtwvg$11.6 Bil

Sponsor Center